ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 860

Interleukin-21, B Cell Activating Factor and Unmethylated CpG Oligodeoxynucleotides Synergize in Promoting Anti-Proteinase 3 Autoantibody Production in Vitro

Nikola Lepse1, Judith Land2, Abraham Rutgers2, Cees G.M. Kallenberg2, Coen A. Stegeman3, Peter Heeringa1 and Wayel H. Abdulahad2, 1Pathology and Medical Biology, University Medical Center Groningen, Groningen, Netherlands, 2Rheumatology and Clinical Immunology, University Medical Center Groningen, Groningen, Netherlands, 3Nephrology, University Medical Center Groningen, Groningen, Netherlands

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: ANCA, autoantibodies and vasculitis, B cells

  • Tweet
  • Email
  • Print
Session Information

Title: Vasculitis: Pathogenesis

Session Type: Abstract Submissions (ACR)

Background/Purpose: Anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitides (AAV) are characterized by the presence of circulating autoantibodies that are often directed against proteinase 3 (PR3). Although the mechanisms that lead to ANCA production in AAV are not clear, bacterial infections have been linked to disease development. We have reported that unmethylated CpG oligodeoxynucleotides (CpG-ODN), which resemble bacterial DNA, in combination with IL-2 enhance ANCA production in vitro. Recent studies have highlighted the role of IL-21 in plasma cell formation and antibody production by synergizing with B cell activating factor (BAFF). This study aimed to assess the involvement of CpG-ODN, IL-21, and BAFF in the mechanisms that contribute to ANCA production in AAV patients.

Methods: Twenty two patients with PR3-AAV (18 in clinical remission, 4 with active disease) and 8 healthy controls (HC) were included in the study. Peripheral blood mononuclear cells (PBMC) were isolated and cultured in vitro for 12 days in the presence of BAFF and IL-21, with or without CpG-ODN. IgG production was measured in culture supernatants by ELISA and PR3-ANCA production was quantified by Phadia EliA and expressed in response units (RU). The percentage of circulating IL-21 producing CD4+ T cells was analyzed by flow cytometry in blood samples stimulated ex vivo with phorbol-myristate-acetate and calcium ionophore in the presence of brefeldin A. CFSE Cell Proliferation Kit was used to assess the effect of BAFF, IL-21, and CpG-ODN on B cell proliferation.

Results: PBMC stimulation with CpG-ODN and IL-2 significantly increased in vitro production of IgG in both HC and patients (P=0,0004) whereas PR3-ANCA production was detected in patient samples only (RU median 0,85 (range 0,00-36,72), compared to 0,10 (0,00-0,14) in HC). Stimulation with BAFF and IL-21 also significantly increased IgG production in HC and patients (P=0,0001) and ANCA production in patient samples (median 0,90 (range 0,00-58,80) versus 0,11 (0,00-0,12) in HC), which could be further augmented by addition of CpG-ODN (median 1,06 (range 0,00-140,00) versus 0,17 (0,10-0,26) in HC). Compared to HC, the proportion of IL-21 producing CD4+ T cells was significantly increased in the circulation of AAV patients. Preliminary data indicate that stimulation with BAFF, IL-21 or the combination of BAFF/IL-21 does not induce B cell proliferation. In contrast, stimulation with CpG-ODN alone induced proliferation in 11,6% of B cells, whereas the combined treatment with BAFF, IL-21 and CpG-ODN induced proliferation in 57,8% of B cells.

Conclusion: IL-21, BAFF and CpG ODN synergize in promoting IgG and PR3-ANCA production from PBMCs of AAV patients in vitro. This effect was associated with substantial B cell proliferation. The increased percentage of IL-21 producing CD4+ T cells in AAV patients suggests the involvement of IL-21 in ANCA production in vivo. Overall, these data indicate that the interplay between endogenous B cell stimuli and bacterial products may contribute to PR3-ANCA reactivation in AAV via B cell activation and proliferation.


Disclosure:

N. Lepse,
None;

J. Land,
None;

A. Rutgers,
None;

C. G. M. Kallenberg,
None;

C. A. Stegeman,
None;

P. Heeringa,
None;

W. H. Abdulahad,
None.

  • Tweet
  • Email
  • Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/interleukin-21-b-cell-activating-factor-and-unmethylated-cpg-oligodeoxynucleotides-synergize-in-promoting-anti-proteinase-3-autoantibody-production-in-vitro/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology